Professor Nabholtz moved in 2014 to the Oncology Centre at King Saud University Medical City in Riyadh, KSA with the mission to build an innovative National and International Cancer Research Program, based upon the fusion of Quantum Optics and Raman Laser Spectroscopy with artificial Intelligence in cancer medicine. He is presently Professor of Medicine at King Saud University and collaborative Professor at the Max Planck Institute and Ludwig Maximilian University in Munich, Germany.

French trained (Board Certified in Internal Medicine, Oncology and Medical Oncology), he spent 16 years in North America as Professor of Oncology at the University of California at Los Angeles (UCLA), USA, and Director of the Cancer Therapy Development Program at the Jonsson Comprehensive Cancer Centre at UCLA. He held, as well, a Professorship at the University of Alberta, Edmonton, Canada.

From 2009 to 2014, he was Chairman of the Department of Medicine and Director of the Division of Clinical and Translational Research at French Federation of Cancer Centres (Jean Perrin Regional Comprehensive Cancer Centre of Auvergne, Clermont-Ferrand, France).

He is also the Founder and past Chairman of the Global Breast Cancer International Research Group (BCIRG) for which he raised more than 170 Million US dollars in global cancer medications development. And more recently Founder and Chairman of the International Cancer Research Group (ICRG).

As Breast Cancer medical oncology and research specialist, his main interests and achievements are related to several topics:

(i) Chemotherapy, in particular taxanes: Beyond being the leading author of the first global registration randomized trial of paclitaxel in advanced breast cancer (1993), he designed the global strategy of development of docetaxel in breast cancer, being chairman of several pivotal registration randomized trials with this agent. He has also developed strategies and participated in the development of Caelyx, 3rd generation taxanes, Epothilone B and Capecitabine.

(ii) Hormone therapy, particularly in the development of third generation aromatase inhibitors. He is the leading author of one of the 2 global registration randomized trials of anastrozole in advanced breast cancer as well as member of the ATAC steering committee (registration trial of anastrozole in early breast cancer). As well, he is chairman of an international neoadjuvant phase III trial with Fulvestrant and CDK 4/6 inhibitor (Palbociclib).

(iii) New biologic modifiers in breast cancer, leading pivotal phase III trials for trastuzumab mainly in adjuvant breast cancer and in the development of new biology-oriented combinations with trastuzumab and new biologic modifiers such as CDK 4/6 Inhibitors.

(iv) Development of the Singularity concept in oncology with integration of means for streamlining the clinical development and integrating Genomics, Transcriptomics and Proteomics in screening, prediction of treatment efficacy and tumour evolution towards true individualized cancer medicine (Singularity). In this context, he is leading the development of an innovative Program in 9 countries based upon the fusion of Quantum Optics// Raman Laser Spectroscopy with Artificial Intelligence in oncology (KSA, Middle-East and Europe) through a collaboration between King Saud University, the Max Planck Institute / Ludwig Maximilian University in Munich, Germany and King Abdallah University of Science and Technology (KAUST Computational Bioscience and Artificial Intelligence Research Centre), KSA. He is also collaborative Professor at the Ludwig Maximilian University in Munich and at the Max Planck Institute in Garching, Germany.

He is the author of more than 400 articles and abstracts as well as more than 1250 international presentations.